MRSN - Mersana Therapeutics, Inc.
| Previous Close | 16.84 |
| Open | 16.72 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 16.60 - 17.04 |
| 52 Week Range | 12.45 - 21.01 |
| Volume | 14,996 |
| Avg. Volume | 127,036 |
| Market Cap | 380.841M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.22 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.75 |
- GlobeNewswire•5 days ago
Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability. XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor. CAMBRIDGE, Mass., April ...
- GlobeNewswire•14 days ago
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
CAMBRIDGE, Mass., April 09, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
- Simply Wall St.•19 days ago
Mersana Therapeutics Inc’s (NASDAQ:MRSN) Profit Outlook
Mersana Therapeutics Inc’s (NASDAQ:MRSN): Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The US$374.22M market-cap company announcedRead More...
- GlobeNewswire•26 days ago
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2. Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin ® Antibody Drug Conjugate Targeting NaPi2b. ...
- Simply Wall St.•27 days ago
Does Mersana Therapeutics Inc’s (NASDAQ:MRSN) Past Performance Indicate A Weaker Future?
Assessing Mersana Therapeutics Inc’s (NASDAQ:MRSN) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
- GlobeNewswire•last month
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business Updates
CAMBRIDGE, Mass., March 21, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
- Benzinga•last month
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
- GlobeNewswire•last month
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
CAMBRIDGE, Mass., March 19, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its proprietary ...
- GlobeNewswire•last month
Mersana Appoints David A. Spellman as Chief Financial Officer
CAMBRIDGE, Mass., March 12, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
- Zacks•2 months ago
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?
Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
- GlobeNewswire•2 months ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 07, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
Capital Cube•4 months agoMersana Therapeutics, Inc. is trading above its 50 day moving average : MRSN-US : December 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- Simply Wall St.•5 months ago
Mersana Therapeutics Inc (MRSN): Earnings Expected To Remain Subdued
In September 2017, Mersana Therapeutics Inc (NASDAQ:MRSN) released its most recent earnings update. Generally, analyst consensus outlook seem bearish, with earnings expected to decline by -98.33% in the upcoming year.Read More...
- Capital Cube•5 months ago
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : November 24, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 75. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Protagonist Therapeutics, Inc., Parallax Health Sciences Inc., Plandai Biotechnology, Inc. and Pieris Pharmaceuticals, Inc. (PTGX-US, PRLX-US, PLPL-US and PIRS-US). Investment Outlook Mersana Therapeutics, Inc. has a ... Read more (Read more...)
- Capital Cube•5 months ago
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MRSN-US : November 22, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- American City Business Journals•6 months ago
A requirement at this Cambridge biotech: Must love dogs
Mersana Therapeutics has accomplished a lot in recent years. The Cambridge biotech signed collaboration deals with drug giants Takeda and Merck KGaA, released promising data on its experimental cancer treatments, and recently raised $75 million in an initial public offering. The company’s chief business officer, Eva Jack, participates in Canine Companions for Independence, a nonprofit program in which volunteer “puppy raisers” like her provide homes for aspiring service dogs before they are placed with children, adults and veterans with disabilities.
- Capital Cube•6 months ago
Mersana Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MRSN-US : October 16, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- American City Business Journals•7 months ago
Boston biotech developing obesity drug pulls down $120M in IPO
A 9-year-old biotech company headquartered in Boston’s Back Bay, Rhythm Pharmaceuticals Inc. has become the fourth local drugmaker to go public this year, raising $120 million in an upsized public offering. Rhythm, which has 15 employees based in a 6,830-square-foot office at 500 Boylston St., sold 7 million shares for $17 each, beating the range it floated in a federal filing just a couple weeks ago of $14-$16. It’s the second-biggest IPO for a Boston-area biotech in what’s so far a slow year, with only Cambridge-based Akcea Therapeutics (AKCA) raising more, with a $144 million IPO in July .
- Capital Cube•7 months ago
Mersana Therapeutics, Inc. – Value Analysis (NASDAQ:MRSN) : September 21, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 69. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc., Bioblast Pharma Ltd. and InVivo Therapeutics Corporation (PIRS-US, PDLI-US, ORPN-US and NVIV-US). Investment Outlook Mersana Therapeutics, Inc. has a fundamental ... Read more (Read more...)
